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Abstract  32 
Maternal pertussis vaccination is associated with higher levels of pertussis 33 
antibodies at birth. We assessed the persistence of pertussis antibodies until 34 
primary vaccination in infants whose mothers received Tdap (tetanus, 35 
diphtheria, acellular pertussis) vaccine during pregnancy. Infants were born at 36 
the Hospital Clinic of Barcelona (Spain) in November 2014. Anti-PT IgG was 37 
determined by ELISA at delivery, between the first and second month of life, 38 
and estimated at 2 months of age. The study included 37 infants whose 39 
mothers received Tdap between 21 and 38 weeks of gestation. Infants 40 
presented a decline in GMC of anti-PT IgG between peripartum and follow-up 41 
levels, 52.7 (95% CI 34.7–80.2) versus 7.5 (95% CI 4.2–13.3) at 2 months of 42 
age (p <0.001). The median half-life of maternal antibodies was 47 days. More 43 
than half (51.4%) the infants presented detectable anti-PT IgG before the start 44 
of primary infant vaccination. 45 
 46 
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Main text 50 
Introduction 51 
Despite high coverage of pertussis infant vaccination, the disease has re-52 
emerged in some industrialized countries, resulting in morbidity and mortality in 53 
young infants [1,2]. In Spain, an increase in pertussis incidence has been 54 
reported since 2010 reaching more than 7 cases per 100,000 inhabitants in 55 
2014. The highest morbidity and mortality has been observed in those younger 56 
than 3 months [3].  57 
 58 
During the last years, various countries have recommended to vaccinate 59 
pregnant women with a pertussis-containing vaccine aiming to protect infants 60 
during the first months of life. More specifically, in December 2012, the Centers 61 
for Disease Control and Prevention (CDC) issued interim recommendations 62 
indicating that women should be revaccinated during each pregnancy, with the 63 
optimal timing for Tdap vaccination being between 27 and 36 weeks of 64 
gestation [4]. The rationale for this public health measure is based on evidence 65 
of transplacental transfer of maternal antibodies [5–7], and the indirect effect of 66 
protecting the mother from an infectious disease, which is important as they are 67 
a frequent source of infection for infant pertussis cases [8].  68 
 69 
Although there are no accepted pertussis antibody levels that provide protection 70 
against pertussis, high levels of pertussis antibodies in cord blood have been 71 
associated with clinical protection against pertussis [9] and a case-control study 72 
estimated a 93% vaccine effectiveness in protecting newborns and infants 73 
against this disease [10]. 74 
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Little data is available on the decay of antibody concentrations in infants from 75 
maternal vaccination during pregnancy until primary infant pertussis 76 
vaccination. The objective of this study was to assess the persistence of 77 
pertussis antibodies (anti-PT IgG) between delivery and until primary infant 78 
vaccination in infants whose mothers received Tdap during pregnancy.  79 
 80 
Material and Methods 81 
Study characteristics 82 
Prospective observational study of infants whose mothers received Tdap 83 
vaccination during pregnancy, and who delivered at Hospital Clinic of Barcelona 84 
(HCB) in November 2014 (PERTU-II Study). Inclusion criteria were maternal 85 
age ≥18 years, Tdap vaccination during the current pregnancy, and maternal 86 
signature of written informed consent. The venous umbilical cord blood samples 87 
were collected consecutively and an infant heel blood sample between the first 88 
and second month of life. In twin pregnancies, a blood sample was collected 89 
only from the firstborn. Pertussis antibody concentrations were determined at 90 
delivery, between the first and second month of life (before starting primary 91 
pertussis infant vaccination), and estimated at 2 months of age. We recruited a 92 
convenience sample, including only cases in which the results of peripartum 93 
and pre-immunisation were available. 94 
 95 
Maternal Tdap vaccination protocol in pregnancy in Catalonia (Spain)  96 
In January 2014, the Department of Health of Catalonia (Spain) recommended  97 
vaccination of all pregnant women with one dose of Tdap from 20 weeks of 98 
gestation, ideally between 27-36 weeks, regardless of their vaccination history 99 
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[11]. The vaccine is administered intramuscularly into the deltoid muscle during 100 
a routine pregnancy check-up. The vaccine used is Triaxis (Sanofi Pasteur 101 
MSD, France), in some countries licensed as Adacel, which contains five 102 
antigens purified from B. pertussis (2.5 µg pertussis toxin, 5 µg filamentous 103 
hemagglutinin, 3 µg pertactin and 5 µg fimbriae 2/3), ≥ 20 IU tetanus toxoid and 104 
≥ 20 IU diphtheria toxoid [12]. 105 
 106 
Laboratory methods 107 
Levels of anti-PT IgG were determined using the Pertussis Toxin ELISA Testkit 108 
IgG/IgA TESTKIT, Sekisui Virotech GmbH, Germany, and expressed as 109 
international units (IU/ml). Absorbance readings were measured and quantified 110 
against an international reference serum, with known amounts of the respective 111 
antibodies (in 2008, preparation No. 6/140 was established as the First 112 
International Standard for Pertussis Antiserum (Human), expressed in IU/ml, 113 
using, as a reference, a pattern drawn up by the FDA: U.S. Human anti-114 
pertussis reference sera lot 3 and lot 4 for IgG antibodies. IU were taken to be 115 
equivalent to Elisa Units (EU) referring to the widely used pattern of the FDA in 116 
studies carried out before 2008) [13–15].The lower limit of detection (LLOD) of 117 
anti-PT IgG was 5 IU/ml. Titers of ≥10 IU/ml were considered as an elevated 118 
cut-off [16]. All samples were analyzed by the HCB microbiology service. 119 
 120 
Collection of variables 121 
The following variables were collected from medical records: maternal date of 122 
birth, country of origin, parity, history of immune system disorders (autoimmune 123 
disease or HIV infection), date of last menstruation, date of administration of 124 
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Tdap vaccine during pregnancy, newborn date of birth, sex and birth weight and 125 
date of infant’s heel blood sample.  126 
 127 
Statistical analysis 128 
In the univariate analysis absolute frequencies were used to describe 129 
categorical variables and means and standard deviation (SD) or 95% 130 
confidence intervals (CI) for quantitative variables with a normal distribution, 131 
and medians and interquartile range otherwise. Anti-PT IgG levels were 132 
described as geometric mean concentrations (GMC) and 95% CI for umbilical 133 
cord blood and infant sera. Values below the LLOD were considered to be half 134 
of the value of detection [6,7]. Antibody concentrations at two months of age 135 
were estimated by linear interpolation using pertussis antibody concentrations 136 
(anti-PT IgG) at delivery and between the first and second month of life.  137 
 138 
For quantitative comparisons of antibody levels at delivery and at 2 months of 139 
age, the Wilcoxon test for paired data was used. Independent sample Mann-140 
Whitney U and Kruskall-Wallis tests were used to assess differences in 141 
antibody levels between groups. The statistical analysis was performed using 142 
the STATA ® statistical package v12.1. Statistical significance was established 143 
as p <0.05. The study was approved by the HCB Clinical Research Ethics 144 
Committee.  145 
 146 
Results 147 
The study included 37 infants whose mothers received Tdap vaccine between 148 
21 and 38 weeks of gestation (3 at 21-26+6 [8.6%], 17 at 27-31+6 [48.6%], 13 at 149 
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32-36+6 [37.1%] and 2 at 37-40 [5.7%] weeks of gestation). In 2 participants, the 150 
date on Tdap vaccination was missing. The Tdap vaccine was administered 151 
between 1 and 19 weeks before delivery (median: 9.1 weeks). No infant was 152 
born before 37 weeks of gestation. The median days between delivery and 153 
collection of the infant blood sample (follow-up) was 45 days (Q1-Q3:42-48). 154 
The demographic and clinical characteristics of the study population are 155 
presented in Table 1.  156 
 157 
Infants of Tdap-vaccinated women (n=37) showed a decline in GMC of anti-PT 158 
IgG between peripartum and follow-up levels of 52.7 IU/ml (95% CI 34.7– 80.2) 159 
in umbilical cord blood and an estimated 7.5 IU/ml (95% CI 4.2–13.3) at 2 160 
months of age (Wilcoxon test paired samples, p <0.001). The magnitude of the 161 
transplacental transfer of anti-PT IgG (GMC) according to gestational age of 162 
Tdap vaccination is shown in Table 2. We also analyzed anti-PT IgG 163 
concentrations according to the time elapsed between Tdap administration and 164 
the gestational age at delivery, but no significant differences were observed 165 
(Mann-Whitney, p = 0.1964).  166 
 167 
We examined whether these findings on Tdap vaccination were expected to 168 
persist over time. It was estimated that, at two months of age, 51.4% of infants 169 
would have detectable titers and 29.7% a high cut-off (≥ 10 IU/ml). We found 170 
that newborns of women vaccinated with Tdap during the third trimester (≥27 171 
weeks of gestation) were expected to sustain the highest GMCs of anti-PT IgG 172 
over time, although the finding was not significant (Mann-Whitney, p=0.0842).  173 
 174 
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Discussion 175 
In our study, anti-PT IgG levels decreased significantly after delivery and the 176 
main factor for higher anti-PT IgG levels at 2 months of age was higher 177 
umbilical cord concentrations (p<0.001). These findings are consistent with the 178 
results of other studies which found that maternal vaccination during pregnancy 179 
is associated with significantly-higher levels of pertussis antibodies at birth [5–180 
7,17,18]. In addition, Maertens et al showed that infants born to vaccinated 181 
women had significantly higher GMC at birth and during the first 2 months of life 182 
compared to the offspring of unvaccinated women, thereby closing the 183 
susceptibility gap for pertussis in infants [5–7,17,18].  184 
 185 
Although not reaching significance, in our study infants of mothers vaccinated 186 
during the third trimester of pregnancy presented anti-PT IgG T levels higher 187 
than the lower limit of quantification at 2 months of age. Previously, Munoz et al 188 
showed that maternal vaccination of 33 women at 30-326 weeks of gestation 189 
with Tdap resulted in high concentrations of pertussis-specific antibodies at 2 190 
months of age [7]. Abu Raya et al suggested that vaccination of pregnant 191 
women with Tdap between 27-30+6 weeks was associated with the highest 192 
umbilical cord GMCs of anti-PT IgG compared with vaccination beyond 31 193 
weeks gestation [17]. However, most recently Eberhardt et al (n=335) 194 
suggested that early-second trimester maternal Tdap immunisation significantly 195 
increase neonatal antibodies [19].  196 
 197 
This study adds evidence to the definition of the half-life of anti-PT IgG in 198 
infancy in the Tdap era. It is reported that the mean half-life of transferred anti-199 
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PT IgG is approximately 43 days [7], or 36 days [20]. Our results show that 200 
maternal antibodies wane with a half-life of 47 days, and that the ability of 201 
maternally-acquired anti-PT IgG to persist is short lived (51.4% with detectable 202 
anti-PT IgG titers at 2 months), meaning that starting infant vaccination at 2 203 
months of age is of great importance.  204 
 205 
Our study has some limitations: we did not collect information on previous 206 
doses of pertussis vaccination nor the personal history of pertussis disease, 207 
making it impossible to evaluate the possible effects of natural boosting on our 208 
findings. However, given the age and country of origin of the subjects studied, it 209 
is almost certain that the majority had received primary vaccination in childhood 210 
with pertussis whole cell vaccine. A higher sample size including premature 211 
infants would have been desirable. Likewise, other pertussis antigens 212 
potentially involved in protection against pertussis infection were not 213 
determined.  214 
 215 
Conclusions 216 
More than half the infants of mothers immunized during late pregnancy 217 
presented pertussis antibodies (anti-PT IgG) before the start of primary infant 218 
vaccination. 219 
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Table 1: Demographic characteristics of women receiving tetanus, diphtheria, and acellular pertussis 
(Tdap) vaccination during pregnancy and their newborns (n=37). 
 
 
Variable Total 
 N (%)  
Maternal age (years)  
Age group 1, 20-24 2 (5.4 %) 
Age group 2, 25-29 4 (10.8 %) 
Age group 3, 30-34 16 (43.2 %) 
Age group 4, 35-39 12 (32.4 %) 
Age group 5, ≥40 3 (8.1 %) 
mean (SD), years 33.8 (4.6) 
Country of birth  
Spain 28 (75.7%) 
Rest of Europe 2 (5.4%) 
Africa 1 (2.7%) 
America 4 (10.8%) 
Asia 2 (5.4%) 
Parity  
≥ 1 15 (40.5%) 
Maternal history of immune system disorders  
Yes 5 (13.5%) 
Twin pregnancy  
Yes 1 (2.7%) 
Weeks of gestation at birth  
median (Q1- Q3), weeks days 40+1 (39+1- 40+5) 
Type of delivery  
Vaginal 22 (59.5%) 
Cesarean 15 (40.5%) 
Sex of newborn  
Male 18 (48.7%) 
Birth weight  
mean (SD), grams 3,159.5 (SD 498.4) 
Table 2: Geometric mean concentrations (GMCs) of immunoglobulin (Ig) G to pertussis toxin (PT) 
during the peripartum period and 2 months after delivery (estimated) stratified by sequential time 
frames of administration of tetanus, diphtheria, and acelullar pertussis (Tdap) vaccine during 
pregnancy.  
 
 
*In 2 cases the date of Tdap administration was missing 
**The GMCs between weeks of gestation groups were compared using Kruskall-Wallis test 
(peripartum, p-value 0.779; pre-immunisation, p-value 0.756) 
***The GMCs between peripartum and pre-immunisation were compared using Wilcoxon test for 
paired data 
 
 
 
 
 
 
 Total Peripartum 
Pre-
immunisation 
 
Variable N (%)  GMC (95% CI)** GMC (95% CI)** 
p-
value*** 
Weeks of gestation at Tdap 
vaccination*  
   
20-26 weeks 3 (8.6%) 29.9 (11.2-79.5) 2.5 (-) 0.317 
27-31 weeks 17 (48.6%) 52.5 (29.4-93.8) 6.8 (2.9-15.6) 0.001 
32-36 weeks 13 (37.1%) 62.5 (27.3-143.6) 8.7 (4.0-19.0) 0.009 
≥37 weeks 2 (5.7%) 83.7 (-) 31.1 (-) 0.180 
Total  37 52.7 (34.7-80.2) 7.5 (4.2-13.3) <0.001 
